Monitor for further selling or commentary around next earnings, current activity is routine for executives managing equity compensation, but continued outflows could signal caution.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 16 $19.40entry
- T+1 · 8mo ago −0.41%α −0.68% · $19.32
- T+5 · 8mo ago −5.21%α −3.16% · $18.39
- T+20 · 7mo ago +18.45%α +14.67% · $22.98
- T+60 · 5mo ago +3.61%α −6.88% · $20.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Claire Mazumdar and President Ryan Cohlhepp of Bicara Therapeutics (BCAX) exercised stock options and sold shares in a coordinated cluster over four days, generating $302,422 in open-market sales. The transactions represent modest insider selling following derivative exercises, with total proceeds under 0.1% of the company's $1.0B market cap.
Key Financial Metrics
Key Facts
- CEO Claire Mazumdar sold 15,000 shares for $282,366 across three days (March 18–20), following full option exercises.
- President Ryan Cohlhepp sold 8,000 shares for $157,257 on March 16 after exercising options.
- All sales were open-market transactions (code S) preceded by derivative exercises (code M).
- Total cash proceeds from selling activity: $302,422 (CEO: $282,366, President: $157,257).
- No open-market purchases or grants; all activity is consistent with pre-planned option monetization.
Financial Impact
$302,422 in insider selling, representing 0.03% of BCAX's $1.0B market cap
Risk Factors
- Perception of insider pessimism if no offsetting buybacks or positive news follow.
- Potential downward pressure if additional executives sell in coming weeks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (12 trades, 7d window) | cluster-BCAX-1774040615039 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers